Cizzle Bio Validates CIZ1B Blood Test for Early Lung Cancer Detection

The validation process at the CLIA-certified OmniHealth facility confirms the test’s readiness for clinical use as a laboratory-developed test. By providing a supplementary tool to low-dose CT screening, the CIZ1B assay aims to refine risk assessment and clarify indeterminate diagnostic findings. Previous studies of the assay reported a 95% sensitivity rate for stage I lung cancer detection alongside a 96% negative predictive value.

Bill Behnke, CEO of Cizzle Bio, noted that the validation represents a milestone in addressing the survival gap in lung cancer treatment, which often hinges on early intervention. While current guidelines suggest annual screening for millions of Americans, low uptake and false positives from standard imaging remain significant hurdles. This new blood-based approach, rooted in research from the University of York, is intended to reduce diagnostic uncertainty and improve patient outcomes. Cizzle Bio plans to expand these validation efforts to additional laboratory partners as it moves toward a broader market rollout.